Smith & Nephew SNATS (NYSE:SNN) Price Target Raised to $35.00

Smith & Nephew SNATS (NYSE:SNN) had its price objective hoisted by equities research analysts at Canaccord Genuity Group from $34.00 to $35.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the medical equipment provider’s stock. Canaccord Genuity Group’s target price points to a potential upside of 0.40% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Finally, Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Trading Down 4.1%

Shares of SNN stock traded down $1.50 on Thursday, hitting $34.86. 1,823,273 shares of the stock traded hands, compared to its average volume of 966,084. The company has a quick ratio of 1.40, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 52 week low of $23.91 and a 52 week high of $38.79. The firm has a 50 day simple moving average of $34.36 and a two-hundred day simple moving average of $34.95.

Institutional Investors Weigh In On Smith & Nephew SNATS

Large investors have recently bought and sold shares of the business. Equity Investment Corp lifted its position in Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 285 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Smith & Nephew SNATS by 13.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 334 shares in the last quarter. Cary Street Partners Financial LLC lifted its holdings in shares of Smith & Nephew SNATS by 1.8% in the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after acquiring an additional 365 shares during the last quarter. GAMMA Investing LLC grew its position in Smith & Nephew SNATS by 11.7% in the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 401 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Smith & Nephew SNATS by 5.0% in the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after acquiring an additional 423 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.